Arq Logo Color Positive RBG.jpg
Arq Publishes its First-Ever ESG Report
September 25, 2024 08:15 ET | Arq, Inc.
GREENWOOD VILLAGE, Colo., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Arq, Inc. (NASDAQ: ARQ) (the "Company" or "Arq"), a producer of activated carbon and other environmentally efficient carbon products,...
Picture1.png
NEWTON GOLF Introduces New Gravity Putter Line, Building on Momentum from Recent Rebranding
September 25, 2024 08:15 ET | Sacks Parente Golf, Inc.
Gravity, the putter division of parent company NEWTON GOLF, introduces five putters in its new premium series CAMARILLO, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NEWTON GOLF, (Nasdaq: SPGC)...
FinWiseBancorpOfficialLogo.png
FinWise Bancorp Announces Strategic Lending Program with PowerPay to Offer Transparent and Affordable Monthly Payments for Home Improvement and Elective Healthcare Purchases
September 25, 2024 08:15 ET | FinWise Bank
MURRAY, Utah, Sept. 25, 2024 (GLOBE NEWSWIRE) -- FinWise Bancorp (NASDAQ: FINW) (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced the launch of a new...
windtree_logos_CMYK_Side1-e1524153991167.png
Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
September 25, 2024 08:15 ET | Windtree Therapeutics
Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many secondary endpoint assessments Study results to be...
Centogene_Logo.png
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology
September 25, 2024 08:00 ET | Centogene NV
Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findingsData from over...
avadel.png
Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent
September 25, 2024 08:00 ET | Avadel Pharmaceuticals plc
– Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data...
Tactile Medical logo.jpg
Tactile Medical Announces Positive Clinical Trial Results in Lymphedema Patients Using Advanced Pneumatic Compression Device Therapy
September 25, 2024 08:00 ET | Tactile Systems Technology, Inc.
MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with...
18_NV5_color_RGB-lg.png
NV5 Announces 4-for-1 Stock Split; Enhances Accessibility of Stock Ownership for Employees and Investors
September 25, 2024 08:00 ET | NV5 Global, Inc.
HOLLYWOOD, Fla., Sept. 25, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, certification, and consulting solutions, announced that it...
Mineralys_Therapeutics_Logo.jpg
Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension
September 25, 2024 08:00 ET | Mineralys Therapeutics, Inc.
– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program...
Cidara.png
Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
September 25, 2024 08:00 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC)...